Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients

Bonnie Spring*, Alan J. Gelenberg, Rob Garvin, Sheri Thompson

*Corresponding author for this work

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

No longer prescribed only for vegetative signs of depression, tricyclic antidepressants also lessen depressive cognitive distortions. Less clear is whether they ameliorate depressed patients' other cognitive deficits in memory, information processing speed, and psychomotor performance. We tested the alternative hypothesis that amitriptyline, because of its anticholinergic and sedative properties, would exacerbate depressed patients' cognitive disturbances. Depressed outpatients received double-blind placebo (n=15), amitriptyline (n=10), or clovoxamine fumarate (n=10), a serotonin reuptake inhibitor relatively lacking in anticholinergic properties. Depression, memory, and psychomotor performance were assessed at baseline and after 7 and 28 days of drug treatment. Depression was alleviated after all treatments, including placebo. Only amitriptyline impaired performance on tests of memory, producing a significant decrement, relative to placebo, after 4 weeks of treatment. None of the treatments adversely affected performance on psychomotor tasks. These findings add to the evidence that antidepressant drugs with high anticholinergic activity can impair memory, despite alleviation of depression.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalPsychopharmacology
Volume108
Issue number3
DOIs
StatePublished - Aug 1 1992

Keywords

  • Amitriptyline
  • Anticholinergic
  • Antidepressants
  • Clovoxamine
  • Memory
  • Tricyclics

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients'. Together they form a unique fingerprint.

  • Cite this